Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study.
Eloïse GalloPhilippe GaudardSophie ProvenchèreFouzia SouabAnaïs SchwabDamien BedagueHugues de La BarreChristian de TymowskiLaysa SaadiBertrand RozecBernard CholleyBruno ScherrerJean-Luc FellahiAlexandre Ouattaranull nullPublished in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2024)
Given the modest reduction in blood loss at the expense of a significant increase in thromboembolic adverse events, aprotinin use in high-risk cardiac surgery patients should be based on a carefully considered benefit-risk assessment.
Keyphrases
- cardiac surgery
- risk assessment
- acute kidney injury
- end stage renal disease
- phase iii
- double blind
- clinical trial
- study protocol
- newly diagnosed
- phase ii
- chronic kidney disease
- cross sectional
- ejection fraction
- atrial fibrillation
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- placebo controlled
- heavy metals
- patient reported outcomes
- weight gain
- body mass index
- climate change
- physical activity